Brendan Smith
Stock Analyst at TD Cowen
(4.93)
# 161
Out of 5,028 analysts
288
Total ratings
59%
Success rate
42.8%
Average return
Main Sectors:
Stocks Rated by Brendan Smith
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRVI Maravai LifeSciences Holdings | Initiated Coverage: Buy | $9 | $8.52 | +5.63% | 1 | Oct 5, 2026 | |
| ABSI Absci | Reiterated: Buy | n/a | $11.53 | - | 11 | Sep 30, 2026 | |
| OABI OmniAb | Reiterated: Buy | $3 → $5 | $4.92 | +1.63% | 12 | Aug 17, 2026 | |
| MXCT MaxCyte | Reiterated: Buy | n/a | $1.08 | - | 12 | Aug 13, 2026 | |
| CDXS Codexis | Reiterated: Hold | $2 | $1.39 | +43.88% | 11 | Aug 11, 2026 | |
| MASS 908 Devices | Reiterated: Buy | n/a | $12.80 | - | 11 | Aug 11, 2026 | |
| PASG Passage Bio | Reiterated: Hold | n/a | $4.12 | - | 11 | Aug 10, 2026 | |
| BLFS BioLife Solutions | Reiterated: Hold | $31 | $38.61 | -19.71% | 13 | Aug 7, 2026 | |
| DNA Ginkgo Bioworks Holdings | Downgraded: Hold | $12 → $9 | $14.98 | -39.92% | 14 | Aug 7, 2026 | |
| HALO Halozyme Therapeutics | Rated: Buy | $96 → $105 | $108.31 | -3.06% | 24 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $13.78 | - | 11 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $20 → $33 | $42.73 | -22.77% | 12 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $5 | $6.09 | -17.90% | 12 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $4.78 | - | 11 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $32.60 | -38.65% | 12 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $9.00 | -22.22% | 12 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $10.07 | -10.63% | 10 | Aug 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $89 → $115 | $205.00 | -43.90% | 18 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $200 | $189.50 | +5.54% | 11 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $410 | $376.76 | +8.82% | 7 | Jul 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $4 → $2 | $1.66 | +20.48% | 10 | Jul 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $2 | $27.38 | -92.70% | 1 | Jul 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $16 | $18.49 | -13.47% | 5 | Jul 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $0.9764 | - | 7 | May 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $62.35 | n/a | 12 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $19.91 | n/a | 11 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $14 → $9 | $12.56 | n/a | 6 | Nov 12, 2024 |
Maravai LifeSciences Holdings
Oct 5, 2026
Initiated Coverage: Buy
Price Target: $9
Current: $8.52
Upside: +5.63%
Absci
Sep 30, 2026
Reiterated: Buy
Price Target: n/a
Current: $11.53
Upside: -
OmniAb
Aug 17, 2026
Reiterated: Buy
Price Target: $3 → $5
Current: $4.92
Upside: +1.63%
MaxCyte
Aug 13, 2026
Reiterated: Buy
Price Target: n/a
Current: $1.08
Upside: -
Codexis
Aug 11, 2026
Reiterated: Hold
Price Target: $2
Current: $1.39
Upside: +43.88%
908 Devices
Aug 11, 2026
Reiterated: Buy
Price Target: n/a
Current: $12.80
Upside: -
Passage Bio
Aug 10, 2026
Reiterated: Hold
Price Target: n/a
Current: $4.12
Upside: -
BioLife Solutions
Aug 7, 2026
Reiterated: Hold
Price Target: $31
Current: $38.61
Upside: -19.71%
Ginkgo Bioworks Holdings
Aug 7, 2026
Downgraded: Hold
Price Target: $12 → $9
Current: $14.98
Upside: -39.92%
Halozyme Therapeutics
Aug 7, 2026
Rated: Buy
Price Target: $96 → $105
Current: $108.31
Upside: -3.06%
Aug 5, 2026
Reiterated: Buy
Price Target: n/a
Current: $13.78
Upside: -
Aug 5, 2026
Reiterated: Hold
Price Target: $20 → $33
Current: $42.73
Upside: -22.77%
Aug 5, 2026
Reiterated: Hold
Price Target: $5
Current: $6.09
Upside: -17.90%
Aug 5, 2026
Reiterated: Hold
Price Target: n/a
Current: $4.78
Upside: -
Aug 5, 2026
Reiterated: Buy
Price Target: $20
Current: $32.60
Upside: -38.65%
Aug 5, 2026
Reiterated: Buy
Price Target: $7
Current: $9.00
Upside: -22.22%
Aug 4, 2026
Reiterated: Buy
Price Target: $9
Current: $10.07
Upside: -10.63%
Aug 3, 2026
Rated: Buy
Price Target: $89 → $115
Current: $205.00
Upside: -43.90%
Jul 28, 2026
Reiterated: Buy
Price Target: $200
Current: $189.50
Upside: +5.54%
Jul 23, 2026
Rated: Buy
Price Target: $410
Current: $376.76
Upside: +8.82%
Jul 15, 2026
Downgraded: Hold
Price Target: $4 → $2
Current: $1.66
Upside: +20.48%
Jul 14, 2026
Downgraded: Hold
Price Target: $2
Current: $27.38
Upside: -92.70%
Jul 9, 2026
Reiterated: Hold
Price Target: $16
Current: $18.49
Upside: -13.47%
May 27, 2026
Reiterated: Buy
Price Target: n/a
Current: $0.9764
Upside: -
May 13, 2025
Reiterated: Buy
Price Target: n/a
Current: $62.35
Upside: n/a
May 6, 2025
Reiterated: Buy
Price Target: n/a
Current: $19.91
Upside: n/a
Nov 12, 2024
Reiterated: Hold
Price Target: $14 → $9
Current: $12.56
Upside: n/a